@article{fdi:010064202,
  title = {{P}rotective antibodies against placental malaria and poor outcomes during pregnancy, {B}enin},
  author = {{T}uikue {N}dam, {N}icaise and {D}enoeud {N}dam, {L}ise and {D}oritchamou, {J}. and {V}iwami, {F}. and {S}alanti, {A}. and {N}ielsen, {M}. {A}. and {F}ievet, {N}adine and {M}assougbodji, {A}. and {L}uty, {A}drian and {D}eloron, {P}hilippe},
  editor = {},
  language = {{ENG}},
  abstract = {{P}lacental malaria is caused by {P}lasmodium falciparum infected erythrocytes that bind to placental tissue. {B}inding is mediated by {VAR}2{CSA}, a parasite antigen coded by the var gene, which interacts with chondroitin sulfate {A} ({CSA}). {C}onsequences include maternal anemia and fetal growth retardation. {A}ntibody-mediated immunity to placental malaria is acquired during successive pregnancies, but the target of {VAR}2{CSA}-specific protective antibodies is unclear. {W}e assessed {VAR}2{CSA}-specific antibodies in pregnant women and analyzed their relationships with protection against placental infection, preterm birth, and low birthweight. {A}ntibody responses to the {N}-terminal region of {VAR}2{CSA} during early pregnancy were associated with reduced risks for infections and low birthweight. {A}mong women infected during pregnancy, an increase in {CSA} binding inhibition was associated with reduced risks for placental infection, preterm birth, and low birthweight. {T}hese data suggest that antibodies against {VAR}2{CSA} {N}-terminal region mediate immunity to placental malaria and associated outcomes. {O}ur results validate current vaccine development efforts with {VAR}2{CSA} {N}-terminal constructs.},
  keywords = {{BENIN}},
  booktitle = {},
  journal = {{E}merging {I}nfectious {D}iseases},
  volume = {21},
  numero = {5},
  pages = {813--823},
  ISSN = {1080-6040},
  year = {2015},
  DOI = {10.3201/eid2105.141626},
  URL = {https://www.documentation.ird.fr/hor/fdi:010064202},
}